The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
University Hospital Ostrava
Ostrava, Czechia
RECRUITINGUniversity Hospital Zurich
Zurich, Canton of Zurich, Switzerland
RECRUITINGsafety measured by registered radiation associated adverse events up to 90 days
safety measured by registered radiation associated adverse events
Time frame: up to 90 days
Radiation associated serious adverse event (at least grade 4 or 5 according to CTCAE v5)
Time frame: As assessed at 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.